# Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

> **NCT00350168** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 647 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** valsartan + amlodipine

## Key facts

- **NCT ID:** NCT00350168
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350168, "Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00350168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*